[Characteristics of SARS-CoV-2 and potential pharmacological treatment]
- PMID: 32700510
- DOI: 10.18388/pb.2020_321
[Characteristics of SARS-CoV-2 and potential pharmacological treatment]
Abstract
In December 2019 in Wuhan, China the first cases of previously unknown, coronaviral infection-induced pneumonia have been reported. The new virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) was named after SARS-CoV due to their similarities and the disease caused by the pathogen is COVID-19 (Coronavirus Disease 2019). On 11 March 2020 WHO (World Health Organization) defined the rapidly increasing number of incidents of COVID-19 as a pandemic. In this review we will present recent information about the SARS-CoV-2 focusing on the origin, clinical picture, diagnostic methods, structure, replication cycle of SARS-CoV-2 and potential pharmaceutical measures against COVID-19.
W grudniu 2019 r. w Chinach odnotowano pierwsze przypadki zapalania płuc spowodowane zakażeniem nieznanym dotychczas koronawirusem, który ze względu na swoje podobieństwo do wirusa SARS-CoV został nazwany SARS-CoV-2, a choroba przez niego wywoływana - COVID-19. Dnia 11 marca 2020 r. Światowa Organizacja Zdrowia ze względu na stale rosnącą liczbę przypadków COVID-19 ogłosiła pandemię wirusa. W tej pracy przeglądowej przedstawiamy dotychczasowe naukowe doniesienia na temat pochodzenia, obrazu klinicznego, diagnostyki, budowy, cyklu replikacyjnego SARS-CoV-2 oraz potencjalnych farmakologicznych sposobach leczenia COVID-19.
Similar articles
-
Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China.Int J Biol Sci. 2020 Apr 6;16(11):1846-1860. doi: 10.7150/ijbs.45018. eCollection 2020. Int J Biol Sci. 2020. PMID: 32398954 Free PMC article. Review.
-
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.Int J Antimicrob Agents. 2020 Aug;56(2):106054. doi: 10.1016/j.ijantimicag.2020.106054. Epub 2020 Jun 10. Int J Antimicrob Agents. 2020. PMID: 32534188 Free PMC article.
-
The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing.Nat Biotechnol. 2020 Sep;38(9):1021-1024. doi: 10.1038/s41587-020-0655-4. Nat Biotechnol. 2020. PMID: 32820257 Free PMC article. No abstract available.
-
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.J Med Virol. 2020 Jun;92(6):552-555. doi: 10.1002/jmv.25728. Epub 2020 Mar 11. J Med Virol. 2020. PMID: 32104915 Free PMC article. Review.
-
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.Virol J. 2020 Oct 15;17(1):154. doi: 10.1186/s12985-020-01415-w. Virol J. 2020. PMID: 33059711 Free PMC article. Review.
Cited by
-
Statins-From Fungi to Pharmacy.Int J Mol Sci. 2023 Dec 29;25(1):466. doi: 10.3390/ijms25010466. Int J Mol Sci. 2023. PMID: 38203637 Free PMC article. Review.
-
Adaptation of medical laboratory scientists to workplace hazards - experiences from the COVID-19 pandemic.Front Public Health. 2022 Sep 28;10:997049. doi: 10.3389/fpubh.2022.997049. eCollection 2022. Front Public Health. 2022. PMID: 36249256 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
